Logo

HOLX

Hologic, Inc.

HOLX

Hologic, Inc. • NASDAQ
$74.97 ▲ 0.23% (+0.17)
Market Cap $16.71 B
52w High $80.31
52w Low $51.90
Dividend Yield 0%
P/E 30.11
Volume 567.80K
Outstanding Shares 222.91M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2025 $1.05B ▲ $402.1M ▲ $187.3M ▼ 17.847% ▼ $0.84 ▼ $316.5M ▼
Q3-2025 $1.024B ▲ $322M ▼ $194.9M ▲ 19.037% ▲ $0.87 ▲ $334M ▲
Q2-2025 $1.005B ▼ $384.3M ▲ $-17.4M ▼ -1.731% ▼ $-0.08 ▼ $76.8M ▼
Q1-2025 $1.022B ▲ $350.7M ▲ $201M ▲ 19.671% ▲ $0.87 ▲ $352M ▲
Q4-2024 $988M $327.7M $178.6M 18.077% $0.76 $328.1M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $1.879B $8.806B $3.964B $4.843B
Q3-2025 $1.879B ▲ $8.806B ▲ $3.964B ▲ $4.843B ▲
Q2-2025 $1.621B ▼ $8.545B ▼ $3.926B ▼ $4.619B ▼
Q1-2025 $1.973B ▼ $8.729B ▼ $3.955B ▼ $4.773B ▼
Q4-2024 $2.334B $9.156B $4.026B $5.13B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $194.9M ▲ $343.3M ▲ $-4.3M ▲ $-40.1M ▲ $305.7M ▲ $330.5M ▲
Q2-2025 $-17.4M ▼ $169.4M ▼ $-324.3M ▼ $-201.7M ▲ $-352.6M ▲ $129.2M ▼
Q1-2025 $201M ▲ $189.3M ▼ $-22M ▲ $-537M ▼ $-378.1M ▼ $142.3M ▼
Q4-2024 $178.6M ▼ $367M ▼ $-595.7M ▼ $-56.8M ▲ $-278.9M ▼ $336.7M ▼
Q3-2024 $194.5M $405.8M $-42.6M $-103.8M $259.1M $371.9M

Revenue by Products

Product Q3-2024Q1-2025Q2-2025Q3-2025
Breast Health
Breast Health
 $390.00M ▲$370.00M ▼$360.00M ▼$370.00M ▲
Diagnostics
Diagnostics
 $440.00M ▲$470.00M ▲$450.00M ▼$450.00M ▲
Gyn Surgical
Gyn Surgical
 $170.00M ▲$170.00M ▲$160.00M ▼$180.00M ▲
Skeletal Health
Skeletal Health
 $20.00M ▲$20.00M ▲$30.00M ▲$30.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has settled into a more normal level after the pandemic testing surge, which explains why sales and profits are lower than the peak a few years ago. Over the most recent two years, revenue has been broadly flat, but profitability has started to improve again as the company adjusts its cost base and shifts mix toward higher‑margin areas. Gross margins remain strong, operating income is recovering from a dip, and net income and earnings per share have rebounded meaningfully from last year, helped in part by share repurchases. Overall, the business looks like it has transitioned from a one‑time COVID boost back to its core women’s health and diagnostics franchises, with margins still healthy even at this more normalized scale.

Balance Sheet

Balance Sheet The balance sheet looks solid and relatively conservative. Total assets have inched up steadily, suggesting ongoing investment without aggressive expansion. Cash holdings are sizable and not far off the level of total debt, which itself has been slowly coming down over time. Shareholders’ equity has been building, reflecting retained earnings and a generally disciplined capital structure. Leverage does not appear excessive, and the company seems to have enough financial flexibility to keep investing in its platforms while managing its obligations comfortably.

Cash Flow

Cash Flow Cash generation is a clear strength. Operating cash flow remains strong even though it has declined from the pandemic peak, and free cash flow is robust after only modest spending on equipment and facilities. The business converts a good portion of its accounting profits into cash, and capital needs are relatively light for a medical technology company of this size. This leaves ample room for continued R&D, selective acquisitions, and shareholder returns, even without rapid revenue growth. The pattern suggests a mature, cash‑rich franchise rather than a capital‑hungry growth story.

Competitive Edge

Competitive Edge Hologic holds leading positions in several niches of women’s health, notably 3D mammography and molecular diagnostics, with a particularly strong presence in U.S. breast imaging. Its large installed base of machines and Panther diagnostic systems creates meaningful switching costs for hospitals and labs, since changing platforms is disruptive and expensive. The company benefits from strong brand recognition, a large patent portfolio, and a reputation for clinically validated, high‑quality products. Competition from large imaging and diagnostics players is intense, but Hologic’s focus, depth in women’s health, and recurring revenue from test kits, service, and upgrades provide a defensible, though not unassailable, competitive moat.

Innovation and R&D

Innovation and R&D Innovation is at the core of Hologic’s strategy, with a clear emphasis on AI‑enabled imaging, molecular diagnostics, and minimally invasive gynecologic procedures. The company has already commercialized important technologies like 3D mammography, advanced AI tools for breast cancer detection, and the fully automated Panther diagnostics platform. Its pipeline includes a next‑generation mammography platform with faster scans and better comfort, more powerful AI algorithms, digital cytology systems, and an expanding menu of diagnostic tests. These efforts deepen customer ties to existing systems, support recurring revenue, and aim to keep Hologic ahead of rivals on accuracy, workflow efficiency, and patient experience. Execution risk and regulatory hurdles remain, but the R&D agenda is focused and closely aligned with its existing strengths.

Summary

Hologic today looks like a high‑margin, cash‑generative medical technology company that is past its pandemic testing spike and back to growing its core women’s health franchises. Revenue has normalized, profitability is recovering, and cash flows are strong relative to the investment required to run and grow the business. The balance sheet is sound, with manageable debt and substantial liquidity. Competitively, the company enjoys a meaningful but not absolute moat built on installed systems, switching costs, brand, and intellectual property. Its innovation roadmap—especially in AI‑driven imaging and molecular diagnostics—offers avenues for long‑term growth and deeper customer integration, but it must continue out‑innovating large global peers and navigate reimbursement and regulatory risks. Overall, it appears to be a financially sturdy, specialized player with durable positions in key women’s health markets and a clear, technology‑driven strategy for the future.

NEWS

November 25, 2025 · 8:08 AM UTC

New Clinical Evidence on Hologic's AI-Powered Mammography Solutions Will Be Unveiled at RSNA

Read more

November 12, 2025 · 8:11 AM UTC

Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking

Read more

November 3, 2025 · 4:01 PM UTC

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2025

Read more

October 29, 2025 · 11:18 AM UTC

HOLX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Hologic to Blackstone and TPG

Read more

October 22, 2025 · 4:56 PM UTC

Hologic Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Hologic, Inc. - HOLX

Read more